Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

Previous clinical studies suggested that - when combined with changes to their diet, exercise and behavioural support - ...

Drugmaker Novo Nordisk (NVO), on Thursday, announced a $199-per-month offer for self-paying patients new to its weight loss ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Almost exactly a year after launching its Obesity Association, the American Diabetes Association (ADA) has recruited Novo ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy ...

In an effort to promote the use of genuine products, Novo Nordisk is offering a one-time first-month offer for Wegovy at $199 ...

Rising teen obesity prompts a surge in Novo Nordisk's Wegovy usage among adolescents, with prescriptions climbing 50% in 2024 ...

Novo Nordisk said on Thursday it would offer temporary discounts to cash-paying customers for its weight-loss drug Wegovy, in ...

As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient ...

Novo Nordisk A/S is selling its blockbuster weight-loss drug Wegovy to new patients at $199 for the first month as easy ...